A
6.02
-0.19 (-3.06%)
| Previous Close | 6.21 |
| Open | 6.26 |
| Volume | 387,747 |
| Avg. Volume (3M) | 1,111,929 |
| Market Cap | 163,001,296 |
| Price / Book | 0.970 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Diluted EPS (TTM) | -2.30 |
| Total Debt/Equity (MRQ) | 19.01% |
| Current Ratio (MRQ) | 22.53 |
| Operating Cash Flow (TTM) | -53.00 M |
| Levered Free Cash Flow (TTM) | -39.36 M |
| Return on Assets (TTM) | -22.88% |
| Return on Equity (TTM) | -38.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Alto Neuroscience, Inc. | Bullish | Bearish |
AIStockmoo Score
0.8
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 7.48% |
| % Held by Institutions | 77.52% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alpha Wave Global, Lp | 30 Jun 2025 | 3,707,757 |
| Armistice Capital, Llc | 30 Jun 2025 | 1,624,000 |
| Vestal Point Capital, Lp | 30 Jun 2025 | 950,000 |
| 72 Investment Holdings, Llc | 30 Jun 2025 | 667,778 |
| Integral Health Asset Management, Llc | 30 Jun 2025 | 400,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Chardan Capital, 149.17%) | Buy |
| Median | 12.50 (107.64%) | |
| Low | 10.00 (HC Wainwright & Co., 66.11%) | Buy |
| Average | 12.50 (107.64%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 29 Sep 2025 | 15.00 (149.17%) | Buy | 4.01 |
| HC Wainwright & Co. | 18 Aug 2025 | 10.00 (66.11%) | Buy | 3.41 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |